ABCD1 p.Arg113Pro
Predicted by SNAP2: | A: D (71%), C: D (85%), D: D (85%), E: D (75%), F: D (95%), G: D (80%), H: D (75%), I: D (85%), K: D (63%), L: D (85%), M: D (80%), N: D (75%), P: D (91%), Q: D (66%), S: D (66%), T: D (71%), V: D (80%), W: D (95%), Y: D (91%), |
Predicted by PROVEAN: | A: N, C: N, D: N, E: N, F: N, G: N, H: N, I: N, K: N, L: N, M: N, N: N, P: N, Q: N, S: N, T: N, V: N, W: D, Y: N, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] ABCD1 mutations and the X-linked adrenoleukodystro... Hum Mutat. 2001 Dec;18(6):499-515. Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, Raymond GV, Cutting GR, Wanders RJ, Moser HW
ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations.
Hum Mutat. 2001 Dec;18(6):499-515., [PMID:11748843]
Abstract [show]
X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene, which encodes a peroxisomal ABC half-transporter (ALDP) involved in the import of very long-chain fatty acids (VLCFA) into the peroxisome. The disease is characterized by a striking and unpredictable variation in phenotypic expression. Phenotypes include the rapidly progressive childhood cerebral form (CCALD), the milder adult form, adrenomyeloneuropathy (AMN), and variants without neurologic involvement. There is no apparent correlation between genotype and phenotype. In males, unambiguous diagnosis can be achieved by demonstration of elevated levels of VLCFA in plasma. In 15 to 20% of obligate heterozygotes, however, test results are false-negative. Therefore, mutation analysis is the only reliable method for the identification of heterozygotes. Since most X-ALD kindreds have a unique mutation, a great number of mutations have been identified in the ABCD1 gene in the last seven years. In order to catalog and facilitate the analysis of these mutations, we have established a mutation database for X-ALD ( http://www.x-ald.nl). In this review we report a detailed analysis of all 406 X-ALD mutations currently included in the database. Also, we present 47 novel mutations. In addition, we review the various X-ALD phenotypes, the different diagnostic tools, and the need for extended family screening for the identification of new patients.
Comments [show]
None has been submitted yet.
No. Sentence Comment
164 X-ALD Mutations Identified in the ABCD1 Gene Allele Exon Mutation Protein Remark fs P42 1 125insC n.d. # fs P84 1 253insC n.d. # E90K 1 268G>A n.d. # S98L 1 293C>T Present S98L 1 293C>T Present R104H 1 311G>A n.d. fs A112 1 337delC Absent # R113C 1 337C>T Present # R113P 1 338G>C n.d. # Q133X 1 397C>T Absent W137X 1 411G>A Absent P143S 1 427C>T n.d. S149N 1 446G>A Present R152S 1 454C>A n.d. R152C 1 454C>T Present R152L 1 455G>T Reduced # S161P 1 481T>C n.d. # R163P 1 488G>C n.d. Y174C 1 521A>G Absent Y174C 1 521A>G n.d. Q177X 1 529C>T Absent Y181C 1 542A>G n.d. fs Y181 1 544ins8bp n.d. # Q195X 1 583C>T n.d. # T198K 1 593C>A n.d. # fs S207 1 621del664bp Absent # SV207-8insAAS 1 622-23ins9bp n.d. # K217E 1 649A>G Present # P218T 1 652C>A n.d. V224E 1 671T>G n.d. # L229P 1 686T>C n.d. L229P 1 686T>C n.d. fs S235 1 706delCGTG n.d. # W242X 1 726G>A Absent G266R 1 796G>A n.d. G266R 1 796G>A n.d. R274W, R280C 1 820C>T, 838C>T n.d. # R285P 1 854G>C n.d. S290X 1 869C>A Absent # E291del 1 871-73delGAG Absent Y296C 1 887A>G n.d. Y296C 1 887A>G n.d. fs E300 IVS1 IVS1+1g>t n.d. # fs E300 IVS1 IVS1-1g>a n.d. # S315X 2 944C>A n.d. # K336M 2 1007A>T n.d. # G343D 2 1028G>A n.d. # R401Q 3 1202G>A Present R401Q 3 1202G>A Present K407X 3 1219A>T n.d. # E427del 4 1279-81delGAA n.d. # Q430X 4 1288C>T n.d. # R464X 4 1390C>T n.d. fs E471 5 1415delAG Absent fs E471 5 1415delAG Absent fs E471 5 1415delAG Absent fs E471 5 1415delAG Absent C511X 6 1533C>A n.d. # R518Q 6 1553G>A Absent fs G528 6 1586-90del Absent # fs Y532 6 1599delG Absent # P543L 6 1628C>T Absent P543L 6 1628C>T Absent fs Q544 6 1628-34duplicated n.d. # fs R545 IVS 6 IVS6+1g>c n.d. # R554H 7 1661G>A Absent fs Q556 7 1670delTG n.d. # (continued) replaced by a pyrimidine (C or T) or vice versa, and transitions, comprising the substitution of one purine by the other, or of one pyrimidine by the other.
X
ABCD1 p.Arg113Pro 11748843:164:266
status: NEW[hide] Molecular organization of peroxisomal enzymes: pro... Arch Biochem Biophys. 2006 Jul 15;451(2):128-40. Epub 2006 May 24. Makkar RS, Contreras MA, Paintlia AS, Smith BT, Haq E, Singh I
Molecular organization of peroxisomal enzymes: protein-protein interactions in the membrane and in the matrix.
Arch Biochem Biophys. 2006 Jul 15;451(2):128-40. Epub 2006 May 24., [PMID:16781659]
Abstract [show]
The beta-oxidation of fatty acids in peroxisomes produces hydrogen peroxide (H2O2), a toxic metabolite, as a bi-product. Fatty acids beta-oxidation activity is deficient in X-linked adrenoleukodystrophy (X-ALD) because of mutation in ALD-gene resulting in loss of very long chain acyl-CoA synthetase (VLCS) activity. It is also affected in disease with catalase negative peroxisomes as a result of inactivation by H2O2. Therefore, the following studies were undertaken to delineate the molecular interactions between both the ALD-gene product (adrenoleukodystrophy protein, ALDP) and VLCS as well as H2O2 degrading enzyme catalase and proteins of peroxisomal beta-oxidation. Studies using a yeast two hybrid system and surface plasmon resonance techniques indicate that ALDP, a peroxisomal membrane protein, physically interacts with VLCS. Loss of these interactions in X-ALD cells may result in a deficiency in VLCS activity. The yeast two-hybrid system studies also indicated that catalase physically interacts with L-bifunctional enzyme (L-BFE). Interactions between catalase and L-BFE were further supported by affinity purification, using a catalase-linked resin. The affinity bound 74-kDa protein, was identified as L-BFE by Western blot with specific antibodies and by proteomic analysis. Additional support for their interaction comes from immunoprecipitation of L-BFE with antibodies against catalase as a catalase- L-BFE complex. siRNA for L-BFE decreased the specific activity and protein levels of catalase without changing its subcellular distribution. These observations indicate that L-BFE might help in oligomerization and possibly in the localization of catalase at the site of H2O2 production in the peroxisomal beta-oxidation pathway.
Comments [show]
None has been submitted yet.
No. Sentence Comment
91 Two peptides (sequences L1: 104 RTFLSVYVARLDGRL ARCIVRKDPRA and L1m: same sequence as L1 but carrying R113P mutation; Arg to Pro at position 113) [25] were custom synthesized with a purity of 98% or higher by Sigma-Genosys (The Woodlands, TX, USA).
X
ABCD1 p.Arg113Pro 16781659:91:102
status: NEWX
ABCD1 p.Arg113Pro 16781659:91:118
status: NEW158 In parallel, a second synthetic peptide with the same amino acid sequence but carrying a single amino acid substitution (R113P) was used for the same analysis (L1m: 104 RTFLSVYVAPLDGRLARCIVRKDP RA).
X
ABCD1 p.Arg113Pro 16781659:158:121
status: NEW166 The sequence of the synthetic peptides L1 and L1m were similar (104 RTFLSVYVARLDGRLARCIVRKDPRA), but L1m carry a R113P mutation (Arg to Pro at position 113).
X
ABCD1 p.Arg113Pro 16781659:166:57
status: NEWX
ABCD1 p.Arg113Pro 16781659:166:113
status: NEWX
ABCD1 p.Arg113Pro 16781659:166:129
status: NEW167 Peptide KD L1 3.3 £ 10¡8 6.0 £ 10¡8 L1m (R113P) 1.1 £ 10¡7 1.6 £ 10¡7 techniques (yeast two-hybrid system and SPR) indicate that ALDP and VLCS physically interact in the peroxisome membrane.
X
ABCD1 p.Arg113Pro 16781659:167:61
status: NEW165 The sequence of the synthetic peptides L1 and L1m were similar (104 RTFLSVYVARLDGRLARCIVRKDPRA), but L1m carry a R113P mutation (Arg to Pro at position 113).
X
ABCD1 p.Arg113Pro 16781659:165:113
status: NEWX
ABCD1 p.Arg113Pro 16781659:165:129
status: NEW